Home | Rich Source

GO BEYOND poorly sourced biologics. Who is who? RichSource for years has private labeled, represented and distributed its own and several other top lab biologic therapeutics (MSCs and acellular nanoparticles). This experience gives RichSource consultants industry “inside knowledge” and continuing relationships with the top MD, CSO and COO heads. Contact RichSource for confidential negotiations for M&As, investing in biologic tissue banks, certified labs, R&D, global commercialization, and other business expansion opportunities that have passed rigid review.
Be informed.

RICHSOURCE consulting developed from years of experience of being on the inside of regenerative nanomedicine. Now with the industry changes, RICHSOURCE is involved in joint venture expansion for tissue banks/ bio labs and large practices to the Caribbean, Mexico and other beneficial locations.

* Having represented multiple bio-ethical, natural HCT/P product lines of tissue banks.
* Access to upcoming new natural life science products.
* Best ozone generator, shockwave, laser devices and other application products.
* Knowledge of FDA HCT/P 351 and 361 regulations and standards for public safety and product quality. AATB and AABB guidelines.
* Knowing the Who's Who in the industry RICHSOURE has access to match the best parties for leading edge projects, clinical trials and off-shore clinic development.
* Developed treatment protocols reference material for a broad spectrum of biological functions and therapeutic potential.
* Creating practice pricing spreadsheets increasing margins.
* Targeted efficient marketing packages to increase patient participation.
* Demonstrating increased patient participation by presenting information about the benefits of Regenerative NanoMedicine and how to introduce medical tourism to your practice.

PRODUCTS AVAILABLE AT RICHSOURCE

Dermacyte Amniotic Wound Care Matrix

Cross-linked to last longer.
Composite layers of amnion.
Sizes cm2: 2.2 cm to 4.8 cm
Five year shelf life.
Q4248. Medicare Part B reimbursement.

See product

Opticyte Amniotic Ocular Matrix

Ophthalmic Repair Graft 8mm - 16mm discs. Single, 10-pack and larger packs available.
Diagnosis, DRG and CPT codes.
Medicare part B. Five year shelf life.

See product

Surgical Repair Graft

Cross-linked to last longer.
Composite layers of amnion.
Sizes: 1 x 1cm to 2 x 3cm
Five year shelf life. Medicare part B.

See product

AATB accredited and FDA registered tissue bank.Physician Office Reimbursement Program.See product page for complete Merakris product information decks and payment & billing guides.Reimbursement support line available Monday-Friday. Please login.

UMBILICAL CORD BLOOD TRANSFUSIONS 25 ml BAGS and 8 M, 15 M and 30M 1 ml/cc Vials are available.

IND submitted Clinical Trial Research for SI Joint has now been FDA approved, October 2021, to begin testing with the top umbilical cord blood product made in FL. Please contact RichSource if you would like to order this product for your research.

Click on the brochure arrow for information on 25 ml UCB bags.

Announcement:
Cord Blood Clinical Trial Receives FDA Authorization

CONTACT FOR
Leading HCT/P Therapeutics
For IND and IRB Studies or
Contract Manufacturing.
FDA Regulation Changes.
Business Partnerships and M & A
Developing Global Medical Tourism

WHY USE RICHSOURCE BUSINESS CONSULTING SERVICES?

PRODUCTS AVAILABLE AT RICHSOURCE

RICHSOURCE® unparalleled consulting gives you a comprehensive up to date insight into the regenerative therapy fields best products, options and resources tested, used or researched by RICHSOURCE®. M & A, partnerships and global medical tourism clinic investing.

Patients

Announcement: Cord Blood Clinical Trial Receives FDA Authorization

WHY USE RICHSOURCE BUSINESS CONSULTING SERVICES?

PRODUCTS AVAILABLE AT RICHSOURCE

RICHSOURCE® unparalleled consulting gives you a comprehensive up to date insight into the regenerative therapy fields best products, options and resources tested, used or researched by RICHSOURCE®. M & A, partnerships and global medical tourism clinic investing.

Patients

Announcement:
Cord Blood Clinical Trial Receives FDA Authorization